Quiz: What's New in COPD for the New Year

Slideshow

Topics include: Role of antibiotics for acute exacerbations; updates on long-term oxygen therapy; COPD-PCI connection, plus more.

Find out what you know about what’s new in COPD diagnosis and management including updates to the NICE guidelines, a study on the use of the CAT, and other developments for 2019. Click through the short quiz below, and good luck.

Related Content
/ image credit ©alesmunt/stock.adobe.com

Sanofi, Regeneron's IL-33 mAb Misses Primary Endpoint in Late-Stage COPD Trial

Grace Halsey
May 30th 2025
Article

Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.

Dupilumab Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study / image courtesy of ResearchGate

Dupilumab for Severe COPD Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study

Grace Halsey
May 27th 2025
Article

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype / image credit ©Waldenmarus/stock.adobe.com

Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype

Grace Halsey
May 23rd 2025
Article

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD / image credit ©cpt88studio/stock.adobe.com

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD

Grace Halsey
May 7th 2025
Article

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

AstraZeneca's Triple Inhaled Therapy Meets Primary Endpoints in Phase 3 Asthma Trials / image credit Alberto Papi, MD, PhD Ferarra University Italy

AstraZeneca's Triple Inhaled Therapy Meets Primary Endpoints in Phase 3 Trials of Uncontrolled Asthma

Grace Halsey
May 2nd 2025
Article

The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.

New Data on Dupilumab Reinforces Its Impact on Chronic Respiratory Diseases

New Data on Dupilumab Reinforces Its Impact on Chronic Respiratory Diseases

Sydney Jennings
May 1st 2025
Article

New clinical trial findings to be presented at ATS 2025 highlights the effectiveness of dupilumab in treating COPD and asthma.

© 2025 MJH Life Sciences

All rights reserved.